Hutchmed(HMDCF)
China - Hong KongBiotechnology
Focus: Hutchmed is a publicly-listed biotech company specializing in oral small-molecule oncology and immunology drugs, headquartered in Hong Kong. The company maintains a diversified pipeline across hematology, nephrology, and gastroenterology with a focus on Asian and global market development.
Profile data last refreshed 23h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
0
About Hutchmed
AI assessmentNot HiringNo open roles listed right now. Follow Hutchmed to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Hutchmed's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Surufatinib
Neuroendocrine TumorsClinical Trials (1)
NCT04814732Expanded Access Program of Surufatinib
N/AHelp build intelligence for Hutchmed
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.